Form 4: DMII Director Catherine Do Boosts Stake

Director Catherine Do of Drugs Made In America Acquisition II Corp. acquired 100,000 ordinary shares from the company's sponsor for no consideration.

Summary

• Catherine Do, a Director of Drugs Made In America Acquisition II Corp. (DMII), acquired 100,000 ordinary shares.
• The shares were acquired from Drugs Made In America Acquisition II LLC, the Issuer's sponsor.
• The transaction occurred on September 26, 2025, and was reported on October 17, 2025.
• No consideration was paid for the acquisition of these shares.
• Following this transaction, Catherine Do beneficially owns 100,000 ordinary shares directly.

Sentiment

Score: 6

Explanation: The acquisition of shares by a director, even for no consideration, generally indicates increased alignment of interests with the company's performance. This is a standard practice within the SPAC structure for sponsor-related share allocations.

Positives

• Increased alignment of interests between Director Catherine Do and shareholders through her direct ownership of 100,000 ordinary shares.
• The acquisition of shares from the sponsor, rather than the open market, suggests a structured arrangement, potentially related to compensation or initial SPAC formation.

Negatives

• The acquisition of shares for "no consideration" could be perceived as a non-cash compensation event, though it is a common practice in SPAC sponsor arrangements.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

No forward-looking statements or guidance were provided in this Form 4 filing.

Industry Context

This transaction is typical for a Special Purpose Acquisition Company (SPAC) where sponsors and directors often receive founder shares or warrants, sometimes for nominal or no consideration, as part of their involvement in the SPAC's formation and operation. Such arrangements are designed to align their interests with the success of the SPAC and its eventual de-SPAC transaction.

Related Party Transactions

• Catherine Do, a Director, acquired 100,000 ordinary shares from Drugs Made In America Acquisition II LLC, the Issuer's sponsor, for no consideration. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholder value. The "no consideration" aspect is typical for SPAC sponsor shares and generally understood within that context.
• Director (Catherine Do): Increased personal stake in the company's future performance.

Key Dates

Keywords

Drugs Made In America Acquisition II Corp., DMII, Catherine Do, insider transaction, Form 4, share acquisition, director ownership, SPAC, beneficial ownership